Provided by Tiger Fintech (Singapore) Pte. Ltd.

REIN THERAPEUTICS INC

1.47
+0.02001.38%
Post-market: 1.470.00000.00%16:48 EDT
Volume:111.27K
Turnover:164.28K
Market Cap:32.57M
PE:-0.51
High:1.55
Open:1.42
Low:1.36
Close:1.45
Loading ...

Shareholder Activism Rises as Rein Therapeutics Adjourns Annual Meeting to July 23

Reuters
·
24 Jun

Top Premarket Decliners

MT Newswires Live
·
13 Jun

Rein Therapeutics pauses dosing in lung disease trial after US FDA places hold

Reuters
·
13 Jun

Rein Therapeutics : Paused Enrollment and Patient Dosing at Its Clinical Trial Sites in United States (U.S.) for Its Phase 2 Renew Trial of Lti-03

THOMSON REUTERS
·
13 Jun

Rein Therapeutics Inc - No Drug-Related Serious Adverse Events Reported for Lti-03 - SEC Filing

THOMSON REUTERS
·
13 Jun

Rein Therapeutics Inc - Renew Trial Continues in Australia, UK, and Europe - SEC Filing

THOMSON REUTERS
·
13 Jun

Rein Therapeutics Pauses U.S. Enrollment for Phase 2 RENEW Trial of LTI-03, Continues in Australia, UK, and Europe

Reuters
·
13 Jun

BRIEF-Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With Ipf

Reuters
·
27 May

Rein Therapeutics Announces First Patient Dosed in Renew Phase 2 Trial of Lti-03 in Patients With Ipf

THOMSON REUTERS
·
27 May

Rein Therapeutics Inc: Topline Interim Data From Renew Is Expected in First Half of 2026

THOMSON REUTERS
·
27 May

Rein Therapeutics : Sales Agreement Prospectus Covering Offering of up to $15.8 Mln of Common Stock

THOMSON REUTERS
·
16 May

Rein Therapeutics Inc Files for Mixed Shelf of up to $150 Mln – SEC Filing

THOMSON REUTERS
·
16 May

Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

Rein Therapeutics Reports Q1 2025 Financial Results: Cash Position Declines, R&D and G&A Expenses Decrease

Reuters
·
16 May

Press Release: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Dow Jones
·
16 May

Rein Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
10 May

Rein Therapeutics Announces Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis with Advanced AI Integration

Reuters
·
01 May

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of Lti-03 in Patients With Ipf

THOMSON REUTERS
·
01 May

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

PR Newswire
·
01 May

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

PR Newswire
·
28 Apr